<DOC>
	<DOCNO>NCT01735071</DOCNO>
	<brief_summary>This study aim assess efficacy safety combination bevacizumab trabectedin without carboplatin adult woman epithelial ovarian cancer first recurrence occur 6-12 month end last ( first second ) platinum-containing regimen . According Bryant Day design primary endpoint proportion progression-free patient 6 month efficacy , proportion patient severe toxicity safety time-point .</brief_summary>
	<brief_title>Bevacizumab Trabectedin +/- Carboplatin Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age≥18years Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Cytological/histological diagnosis epithelial ovarian cancer Progression free interval 612 month ( calculate first day last cycle previous last platinumbased chemotherapy date progression confirmation radiologic image ) One two previous platinumbased chemotherapy line Measurable disease accord RECIST version 1.1 Life expectancy ≥ 12 week Patients must able receive dexamethasone equivalent , premedication trabectedin Written inform consent give enrolment accord International Conference Harmonization/ Good Clinical Practice ( ICH/GCP ) . Prior treatment trabectedin Prior progression therapy contain bevacizumab vascular endothelial growth factor ( VEGF ) pathwaytarget therapy Preexisting grade &gt; 1 sensitive/motor neurologic disorder Current recent ( within 30 day first study dose ) treatment another investigational drug Surgery ( include open biopsy ) within 4 week prior first plan dose bevacizumab Current recent ( within 10 day prior first study drug dose ) use fulldose oral parenteral anticoagulant thrombolytic agent therapeutic purpose ( except line patency , case international normalize ratio ( INR ) must maintain 1.5 ) . Post operative prophylaxis low molecular weight heparin sc allow Inadequate bone marrow function : absolute neutrophil count ( ANC ) : &lt; 1.5 x 109/l , platelet count &lt; 100 x 109/l haemoglobin &lt; 9 g/dl . Patients may transfuse maintain haemoglobin value ≥9 g/dl Inadequate coagulation parameter : activate partial thromboplastin time ( APTT ) &gt; 1.5 x upper limit normal ( ULN ) INR &gt; 1.5 Inadequate liver function , define : serum ( total ) bilirubin &gt; ULN institution AST/serum glutamicoxaloacetic transaminase ( SGOT ) ALT/ serum glutamicpyruvic transaminase ( SGPT ) &gt; 2.5 x ULN Inadequate renal function : serum creatinine &gt; 1.5 mg/dL &gt; 132 micromol/L urine dipstick proteinuria &gt; = 2+ &gt; 1g protein 24hour urine collection History evidence brain metastasis spinal cord compression Pregnant , breastfeed woman woman child bear potential , agree use medically acceptable method contraception treatment period 6 month discontinuation treatment History evidence thrombotic hemorrhagic disorder ; include cerebrovascular accident , stroke transient ischemic attack subarachnoid haemorrhage within 6 month prior first study treatment Uncontrolled hypertension ( sustain systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg despite antihypertensive therapy ) clinically significant ( i.e . active ) cardiovascular disease , include : myocardial infarction unstable angina within 6 month prior first study treatment , New York Heart Association grade II great congestive heart failure , serious cardiac arrhythmia require medication History bowel obstruction , include subocclusive disease , relate underlying disease history abdominal fistula , gastrointestinal perforation intraabdominal abscess . Evidence rectosigmoid involvement pelvic examination bowel involvement CT scan clinical symptom bowel obstruction Nonhealing wound , ulcer bone fracture hepatitis C virus ( HCV ) positivity Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>trabectedin</keyword>
	<keyword>carboplatin</keyword>
	<keyword>randomize trial</keyword>
	<keyword>phase II</keyword>
</DOC>